Angina Global Market Report 2024

Angina, also referred to as angina pectoris, presents as chest pain or discomfort caused by reduced blood flow to the heart muscle, typically due to blockages or narrowing of coronary arteries from atherosclerosis.

The primary types of angina include angina pectoris, unstable angina, Prinzmetal angina, and others. Angina pectoris, associated with coronary heart disease, results in chest pain or discomfort due to inadequate blood supply to the heart, often caused by arterial blockages. Treatment options range from lifestyle adjustments and medications to procedures such as angioplasty, stenting, and coronary bypass surgery. Commonly prescribed medications include beta-blockers, nitrates, calcium channel blockers, and angiotensin-converting enzyme inhibitors, utilized across various healthcare settings such as clinics and hospitals.

The angina market research report is one of a series of new reports that provides angina market statistics, including angina industry global market size, regional shares, competitors with an angina market share, detailed angina market segments, market trends, and opportunities, and any further data you may need to thrive in the angina industry. This angina market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The angina market size has grown strongly in recent years. It will grow from $10.11 billion in 2023 to $10.71 billion in 2024 at a compound annual growth rate (CAGR) of 5.9%. In the historical period, growth can be explained by factors such as the rising prevalence of coronary heart disease, greater usage of vasodilators, increased incidence of myocardial ischemia, enhanced diagnostic capabilities, and expanded utilization of imaging techniques.

The angina market size is expected to see strong growth in the next few years. It will grow to $13.61 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period is anticipated due to the increasing prevalence of chronic angina pectoris, rising numbers of drug approvals and clinical research activities, growing demand from retail pharmacies, heightened awareness about cardiovascular health, and escalating demand for medications. Key trends expected in the forecast period include advancements in early diagnostic technologies, developments in angioplasty and stenting procedures, innovations in gene therapy approaches, increasing demand for coronary stents, and advancements in treatments for coronary artery disease.

The anticipated increase in coronary artery disease cases is set to drive growth in the angina market. Coronary artery disease (CAD), also known as coronary heart disease (CHD) or ischemic heart disease (IHD), involves the narrowing or blockage of coronary arteries, critical for supplying blood, oxygen, and nutrients to the heart muscle. Lifestyle changes, environmental factors, and genetic predispositions contribute to the rising prevalence of CAD. Angina serves as a pivotal indicator for identifying and assessing CAD prevalence, guiding medical evaluations, risk stratification, treatment decisions, and public health strategies. For instance, the American Heart Association reported a rise in adults living with CAD in the U.S. from 18.2 million in 2021 to approximately 19.3 million in January 2023, underscoring the driving force behind the angina market's expansion.

Leading firms in the angina market are focusing on developing innovative medications such as metoprolol tartrate tablets to enhance treatment efficacy for CAD and related conditions. Metoprolol tartrate tablets, a widely used cardiovascular medication, target various conditions such as angina, hypertension, and heart failure. For example, Zydus received FDA approval in April 2023 to produce generic versions of Metoprolol Tartrate Tablets USP in strengths of 25 mg, 50 mg, and 100 mg, bolstering treatment options for cardiovascular ailments and supporting patient outcomes.

In March 2024, Novo Nordisk acquired Cardior Pharmaceuticals for $1.1 billion (€1.025 billion), aiming to fortify its cardiovascular therapeutic pipeline. This acquisition integrates Cardior's RNA-based therapeutics, notably CDR132L, currently in Phase II clinical trials for heart failure treatment, thereby expanding Novo Nordisk's capabilities in managing cardiovascular diseases. Cardior Pharmaceuticals, headquartered in Germany, specializes in angiotensin-converting enzyme inhibitors, contributing further to Novo Nordisk's strategic expansion in cardiovascular care.

Major companies operating in the angina market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co Inc., Bayer AG, Sanofi S.A., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline Plc, Eli Lilly and Company, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Troikaa Pharmaceuticals Ltd, Amgen Inc., Dr. Reddy's Laboratories, ViroMed Co. Ltd., Lee’s Pharmaceutical Holdings, Kuhnil Pharmaceutical, LegoChem Biosciences, Axus Cardium Pharmaceuticals, Juventas Therapeutics, Milestone Pharmaceuticals.

North America was the largest region in the angina market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the angina market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the angina market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The angina market consists of revenues earned by entities by providing treatments for stable angina, and microvascular angina. The market value includes the value of related goods sold by the service provider or included within the service offering. The angina market also includes sales of anticoagulants and statins. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.